References
- Johnell O, Kanis JA. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16: S3–7.
- Lindsay R, Silverman SL, Cooper C, et al Risk of new vertebral fracture in the year following fracture. JAMA 2001; 285: 320–3.
- Lorentzon M, Mellstrom D, Haug E,et al Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007; 92: 497–03.
- Kanis JA, Johansson H, Johnell O, Oden A, el al Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16: 737–42.
- Kemmler W, Lauber D, Weineck J, et al. Benefits of 2 years of intense exercise on bone density, physical fitness and blood lipids in early postmenopausal osteopenic women. Arch Intern Med. 2004; 164: 1084–91.
- Lord SR, Sherrington C, Menz HB. Falls in older people: risk factors and strategies for prevention. Cambridge: Cambridge University Press; 2001. p. 1–260.
- NIH-Consensus development panel on optimal calcium intake. JAMA 1994; 272: 1942.
- Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353–73.
- Bischoff-Ferrari HA, Dawson-Hughes B, Willed W, et al. Fall prevention by vitamin D treatment: a meta-analysis of randomized controlled trials. JAMA. 2004; 291: 1999–2006.
- Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581–89.
- Kanis JA, Johnell O, Dawson A, etal The 10 year probabilities of osteoporotic fractures according to BMD and diagnostics thresholds. Osteoporos Int 2001; 12: 989–95.
- Rossouw JE, Prentice RL, Manson JE, etal Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–77.
- De Villiers TJ, Bagratee JS, Dalmeyer JP, et al. South African Menopause Society Council Revised Consensus Position Statement on Menopausal Hormone Therapy. S Afr Med J 2007; 97: 354–7.
- Ettinger B, Black DM, Mitlack BH, etal Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999; 282: 637–15.
- Marti no S, Cauley JA, Barrett-Connor E, et al. For CORE investigators. Continuing outcomes relevant to evista; breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–61.
- Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial (RUTH Trial). J Bone Miner Res 2008; 23(1): 112–20.
- Colon-Emeric C. (Editorial). Ten vs five years of bisphosphonate treatment for osteoporosis. JAMA 2006; 296: 2968–9.
- Woo S-B, Hellstein JW, Kalmar JR. Review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753–61.
- Hough FS ef a. Position paper of the National Osteoporosis Foundation of South Africa on the use of parathyroidhormone (PTH 1 -34) in the treatment of osteoporosis. S Afr Med J 2004; 94: 175–7.
- Reginster JX Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816–22.